Jonathan Millar, MD
Clinical Lecturer, Intensive Care Medicine, Roslin Institute, University of Edinburgh
Jonathan Millar is an Honorary Specialist Registrar, Intensive Care Medicine, South East of Scotland, and Clinical Lecturer, Roslin Institute, University of Edinburgh. His research interests include cell therapies for ARDS, unsupervised machine learning approaches to clinical phenotyping in acute severe respiratory failure, and large animal models of critical illness, including models of ECMO. He has previously worked under Prof John Fraser, at the Critical Care Research Group, University of Queensland, and with Prof Danny McAuley, at the Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University Belfast.
CME Faculty Disclosure: It is the policy of EB Medicine to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-sponsored educational activities. All faculty participating in the planning or implementation of a sponsored activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. In compliance with all ACCME Essentials, Standards, and Guidelines, all faculty for this CME activity were asked to complete a full disclosure statement. The speaker did not report any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) discussed in this educational presentation.
In the last five years, the introduction of cellular therapies has revolutionized the management of haematological cancers. The success of this approach has encouraged others to seek novel means to treat a variety of critical illness syndromes. In this talk, we will review the current state of cell-based immune modulation for ARDS and sepsis. We will address the classification and biology of investigational cell therapies, alongside a discussion of the challenges associated with scaling them for widespread clinical use.
By the end of this lecture the attendee will be able to:
- Appreciate the spectrum of available cellular therapies
- Describe the biology of cell therapies in the context of critical illness
- Discuss the current evidence base for cell therapies and be aware of important ongoing trials
- Understand the challenges associated with delivering cell therapy in the clinic
This lecture is equal to 1 CPD Point, 1 AMA PRA Category 1 Credit™, and 1 CE Contact Hour.
Live webinar time:
Chicago - Tue 6th July 2021 at 7am
London - Tue 6th July 2021 at 1pm
Sydney - Tue 6th July 2021 at 10pm
To check the time in your city, click here
If you can't make the live recording, don't worry, the recording will be available shortly after
Additional CME Info
Release Date: February 1, 2020, Termination Date: January 31, 2023
Accreditation: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of EB Medicine and Continulus. EB Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation: EB Medicine designates this internet enduring material for a maximum of 1 AMA PRA Category 1 Credit™ per lecture. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Commercial Support: This activity received no commercial support.
Earning Credit: In order to earn CME credit, the participant must take the pre-test, listen to the lecture, take the CME post-test, and complete the post-test evaluation.